Friday, January 24, 2014 7:32:36 PM
As for early halt during accrual versus afterward, it does happen, there's a long history of it. Not only has it happened, but it's even happened with fewer than 1/3rd of the planned patient population enrolled (e.g. the PTCA trial in '95 which stopped with 1500 out of a planned 4800 patients).
Furthermore, this trial is in a particularly unique situation favorable to early halt relative to accrual completion because of how new enrollment (but not ongoing treatment) was paused from '08-'11. Patient count may be low but observed patient-months and events are disproportionately large to that count (if it had just started in 2011 instead of 2006). Even if the 33 existing patients had far longer PFS than SoC, their first treatment schedule (the 120 weeks) had already ended by the time enrollment resumed and was years past by the time the first interim was triggered. My point?
The first possibility is that they at long last, sad but likely, contributed to the 66 events. So it didn't really matter how slow enrollment has been because it truly started so long ago.
The second possibility is that they've been progression free and alive for so long that the distance between the K-M curves is enormous and however else the 66 events were comprised (e.g. resumed enrollment was slightly further along than we expected and SoC performed...well, normally for SoC), the treatment advantage has already proven huge.
Either way, there have been a great many patient-months observed in the study.
Obviously this is a very bullish scenario. It's worth repeating that by far, historically, the most common decision is to simply continue. I'm just saying that this trial's particular, elongated history and careful design makes it somewhat (greater than 0%) more likely than any given other trial to achieve this unusual early outcome (if the treatment works).
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM